NBTXR3 activated by radiotherapy in combination with nivolumab or pembrolizumab in patients with advanced cancers: results from an ongoing dose escalation phase I trial (Study 1100)

Pour en savoir plus sur nos technologies, nos collaborations, nos essais cliniques et d’autres sujets, contactez-nous.